Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fremanezumab for Interstitial Cystitis-Bladder Pain Syndrome
NCT04447729Phase 2Withdrawn
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Oct 2020
- Primary completion
- Feb 2022
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
A Phase 2 trial of fremanezumab in interstitial cystitis (IC), sponsored by Teva Pharmaceutical Industries Ltd.. Planned start Oct 2020; status: withdrawn.
02
Drugs
fremanezumab
03
Conditions
interstitial cystitis (IC)
Beyond the preview
Go deeper on NCT04447729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04447729.